6533b85cfe1ef96bd12bd4b4

RESEARCH PRODUCT

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

Markus MöhlerMatthias TheobaldMartin R. BergerThomas WehlerJutta HerzogClaudine GrafInes GockelPeter R. GalleHauke LangCarl C. Schimanski

subject

medicine.medical_specialtyCancer ResearchHematologyCetuximabintegumentary systembusiness.industryGeneral MedicineMinocyclineRashDermatologydigestive system diseasesSurgeryMetronidazoleOncologyInternal medicineMonoclonalmedicinePrednisolonemedicine.symptomAntibiotic prophylaxisbusinessneoplasmsmedicine.drug

description

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation.

yearjournalcountryeditionlanguage
2013-08-07Journal of Cancer Research and Clinical Oncology
10.1007/s00432-013-1483-4http://dx.doi.org/10.1007/s00432-013-1483-4